IL3RA and acute myeloid leukemia: In conclusion, our studies provide novel insights into the field of adoptive cell therapy for AML, underlying the significant anti-leukaemia activity exerted by an allogeneic, off-the-shelf approach based on CAR.CD123-NK cells that represents a product that is equally as effective as CAR T cells but is characterized by a more favourable safety profile with regard to both haematopoietic and endothelial on-target off-tumour toxicity.